PEG-G-CSF has a 6- to 8-fold longer half-life than G-CSF in vivo, which allows the protein to be effective when administered once per chemotherapy cycle (typically once every 3 weeks) to cancer patients [12]. This evidence concerns the gene CSF3 and cancer.